Biotech lobbyists are happier this morning in PA following that State's Senate committee approving a bill that would call for strict limitations on substitution of biosimilars -- thus making it harder. The proposed Bill still has to go to the floor to gain passage but is one step closer. Amgen and BIO both hailed the development as one that "will instill confidence in the utilization of biosimilar products among patients, physicians, and pharmacists."
Governor Brown in California struck down a similarly worded bill in the past few months. So far, no other States have passed such legislation except North Dakota. The GPhA, Pennsylvania Pharmacists Association, and the National Association of Chain Drug Stores all oppose the measure. They believe limits on substitution will only drive up costs. See Pharmalot.
Posted by Bruce Lehr Nov 18th 2013.